NK1 receptor antagonists and dexamethasone as anticancer agents in vitro and in a model of brain tumours secondary to breast cancer

Anti-Cancer Drugs

Volumn 24, Issue 4, 2013, Pages 344-354

  Lewis, Kate M ^a   Harford Wright, Elizabeth ^a   Vink, Robert ^a   Ghabriel, Mounir N ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

brain metastases; dexamethasone; Emend; NK1 receptor antagonist; substance P

Indexed keywords

APREPITANT; DEXAMETHASONE; GLIAL FIBRILLARY ACIDIC PROTEIN; N ACETYLTRYPTOPHAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; BRAIN METASTASIS; BREAST CANCER; CANCER CELL; CELL DIVISION; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; CORPUS STRIATUM; EXPERIMENTAL MODEL; GLIA CELL; HYPOTHESIS; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; WALKER CARCINOMA; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTES; BRAIN EDEMA; BRAIN NEOPLASMS; CALCIUM-BINDING PROTEINS; CARCINOMA; CELL LINE, TUMOR; CORPUS STRIATUM; DEXAMETHASONE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICROFILAMENT PROTEINS; MICROGLIA; MODELS, BIOLOGICAL; MORPHOLINES; NEOPLASM PROTEINS; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTORS, NEUROKININ-1; TRYPTOPHAN; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84875053263     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835ef440     Document Type: Article

References (95)

1. Bray F, Engholm G, Hakulinen T, Gislum M, Tryggvadottir L, Storm HH, et al. Trends in survival of patients diagnosed with cancers of the brain and nervous system, thyroid, eye, bone, and soft tissues in the Nordic countries 1964-2003 followed up until the end of 2006. Acta Oncol 2010; 49: 673-693
2. AIHW, AACR. Cancer in Australia: An overview, 2010. Cancer series no. 60. Canberra: AIHW; 2010
3. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002; 94: 2698-2705
4. Villa S, Weber DC, Moretones C, Manes A, Combescure C, Jove J, et al. Validation of the new Graded Prognostic Assessment scale for brain metastases: A multicenter prospective study. Radiat Oncol 2011; 6:23
5. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 2012; 82:2111-2117
6. Jelsma R, Bucy PC. The treatment of glioblastoma multiforme of the brain. J Neurosurg 1967; 27:388-400
7. Lesniak MS, Gabikian P, Tyler BM, Pardoll DM, Brem H. Dexamethasone mediated inhibition of local IL-2 immunotherapy is dose dependent in experimental brain tumors. J Neurooncol 2004; 70:23-28
8. McGirt MJ, Chaichana KL, Gathinji M, Attenello F, Than K, Ruiz AJ, et al. Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas. Neurosurgery 2008; 63:286-291
9. Alpert E, Seigerman C. Steroid withdrawal psychosis in a patient with closed head injury. Arch Phys Med Rehabil 1986; 67:766-769
10. McCluskey J, Gutteridge DH. Avascular necrosis of bone after high doses of dexamethasone during neurosurgery. Br Med J (Clin Res Ed) 1982; 284:333-334
11. Fast A, Alon M,Weiss S, Zer-Aviv FR. Avascular necrosis of bone following short-Term dexamethasone therapy for brain edema. Case report. J Neurosurg 1984; 61:983-985
12. Ruhlmann CH, Herrstedt J. Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 2012; 12:139-150
13. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapyinduced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23:2822-2830
14. Herrstedt J, Muss HB,Warr DG, Hesketh PJ, Eisenberg PD, Raftopoulos H, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005; 104:1548-1555
15. Hesketh PJ, Grunberg SM, Gralla RJ,Warr DG, Roila F, de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapyinduced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-4119
16. Navari RM. Aprepitant: A neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 2004; 4:715-724
17. Navari RM. Inhibiting substance P pathway for prevention of chemotherapyinduced emesis:Preclinical data, clinical trials of neurokinin-1 receptor antagonists. Support Cancer Ther 2004; 1:89-96
18. Hesketh PJ, Grunberg SM, Herrstedt J, de Wit R, Gralla RJ, Carides AD, et al. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting:Effect of gender on treatment response. Support Care Cancer 2006; 14:354-360
19. Moroz MA, Huang R, Kochetkov T, Shi W, Thaler H, de Stanchina E, et al. Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: Treatment efficacy and toxicity in U87 and C6 intracranial gliomas. Clin Cancer Res 2011; 17:3282-3292
20. Villeneuve J, Galarneau H, Beaudet MJ, Tremblay P, Chernomoretz A, Vallieres L. Reduced glioma growth following dexamethasone or antiangiopoietin 2 treatment. Brain Pathol 2008; 18:401-414
21. Wolff JE, Guerin C, Laterra J, Bressler J, Indurti RR, Brem H, et al. Dexamethasone reduces vascular density and plasminogen activator activity in 9L rat brain tumors. Brain Res 1993; 604:79-85
22. Badruddoja MA, Krouwer HG, Rand SD, Rebro KJ, Pathak AP, Schmainda KM. Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps. Neuro Oncol 2003; 5:235-243
23. Guerin C,Wolff JE, Laterra J, Drewes LR, Brem H, Goldstein GW. Vascular differentiation and glucose transporter expression in rat gliomas:Effects of steroids. Ann Neurol 1992; 31:481-487
24. Tazik S, Johnson S, Lu D, Johnson C, Youdim MB, Stockmeier CA, et al. Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. Neurotox Res 2009; 15:284-290
25. Bavaresco L, Bernardi A, Braganhol E, Wink MR, Battastini AM. Dexamethasone inhibits proliferation and stimulates ecto-50-nucleotidase/ CD73 activity in C6 rat glioma cell line. J Neurooncol 2007; 84:1-8
26. Piette C, Deprez M, Roger T, Noel A, Foidart JM, Munaut C. The dexamethasone-induced inhibition of proliferation, migration, and invasion in glioma cell lines is antagonized by macrophage migration inhibitory factor (MIF) and can be enhanced by specific MIF inhibitors. J Biol Chem 2009; 284:32483-32492
27. Zhang C, Beckermann B, Kallifatidis G, Liu Z, Rittgen W, Edler L, et al. Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma. Int J Oncol 2006; 29:1295-1301
28. Sur P, Sribnick EA, Patel SJ, Ray SK, Banik NL. Dexamethasone decreases temozolomide-induced apoptosis in human gliobastoma T98G cells. Glia 2005; 50:160-167
29. Kim YS, Park JS, Jee YK, Lee KY. Dexamethasone inhibits TRAIL- And anti-cancer drugs-induced cell death in A549 cells through inducing NF-kappaB-independent cIAP2 expression. Cancer Res Treat 2004; 36: 330-337
30. Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance-P receptors in human primary neoplasms: Tumoral and vascular localization. Int J Cancer 1995; 61:786-792
31. Huang WQ, Wang JG, Chen L, Wei HJ, Chen H. SR140333 counteracts NK-1 mediated cell proliferation in human breast cancer cell line T47D. J Exp Clin Cancer Res 2010; 29:55-61
32. Schulz S, Stumm R, Rocken C, Mawrin C. Immunolocalization of full-length NK1 tachykinin receptors in human tumors. J Histochem Cytochem 2006; 54:1015-1020
33. Singh D, Joshi DD, Hameed M, Qian J, Gascon P, Maloof PB, et al. Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells:Implications for bone marrow metastasis. Proc Natl Acad Sci USA 2000; 97:388-393
34. Khare VK, Albino AP, Reed JA. The neuropeptide/mast cell secretagogue substance P is expressed in cutaneous melanocytic lesions. J Cutan Pathol 1998; 25:2-10
35. Allen JM, Hoyle NR, Yeats JC, Ghatei MA, Thomas DG, Bloom SR. Neuropeptides in neurological tumours. J Neurooncol 1985; 3: 197-202
36. Munoz M, Rosso M, Covenas R. The NK-1 receptor: A new target in cancer therapy. Curr Drug Targets 2011; 12:909-921
37. Munoz M, Rosso M, Perez A, Covenas R, Rosso R, Zamarriego C, et al. Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest Ophthalmol Vis Sci 2005; 46:2567-2570
38. Munoz M, Rosso M, Covenas R, Montero I, Gonzalez-Moles MA, Robles MJ. Neurokinin-1 receptors located in human retinoblastoma cell lines: Antitumor action of its antagonist, L-732,138. Invest Ophthalmol Vis Sci 2007; 48:2775-2781
39. Munoz M, Rosso M, Perez A, Covenas R, Rosso R, Zamarriego C, et al. The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides 2005; 39:427-432
40. Friess H, Zhu Z, Liard V, Shi X, Shrikhande SV,Wang L, et al. Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest 2003; 83:731-742
41. Rosso M, Robles-Frias MJ, Covenas R, Salinas-Martin MV, Munoz M. The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumour Biol 2008; 29:245-254
42. Bigioni M, Benzo A, Irrissuto C, Maggi CA, Goso C. Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231. Anticancer Drugs 2005; 16:1083-1089
43. Akazawa T, Kwatra SG, Goldsmith LE, Richardson MD, Cox EA, Sampson JH, et al. A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. J Neurochem 2009; 109:1079-1086
44. Munoz M, Perez A, Covenas R, Rosso M, Castro E. Antitumoural action of L-733,060 on neuroblastoma and glioma cell lines. Arch Ital Biol 2004; 142:105-112
45. Kast RE. Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-Approved anti-emetic aprepitant might retard cerebral glioblastoma growth: A new hypothesis to an old question. Clin Transl Oncol 2009; 11:408-410
46. Munoz M, Rosso M, Robles-Frias MJ, Salinas-Martin MV, Rosso R, Gonzalez-Ortega A, et al. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab Invest 2010; 90: 1259-1269
47. Munoz M, Rosso M. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs 2010; 28:187-193
48. Harford-Wright E, Lewis KM, Vink R. Towards drug discovery for brain tumours:Interaction of kinins and tumours at the blood brain barrier interface. Recent Pat CNS Drug Discov 2011; 6:31-40
49. Palma C, Bigioni M, Irrissuto C, Nardelli F, Maggi CA, Manzini S. Anti-Tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer 2000; 82:480-487
50. Erin N, Akdas Barkan G, Harms JF, Clawson GA. Vagotomy enhances experimental metastases of 4THMpc breast cancer cells and alters substance P level. Regul Pept 2008; 151:35-42
51. Korcum AF, Sanlioglu S, Aksu G, Tuncel N, Erin N. Radiotherapy-induced decreases in substance P levels may potentiate melanoma growth. Mol Med Report 2009; 2:319-326
52. Harris DT, Witten M. Aerosolized substance P protects against cigarette-induced lung damage and tumor development. Cell Mol Biol (Noisy-le-grand) 2003; 49:151-157
53. Manske JM, Hanson SE. Substance-P-mediated immunomodulation of tumor growth in a murine model. Neuroimmunomodulation 2005; 12: 201-210
54. Erin N, Zhao W, Bylander J, Chase G, Clawson G. Capsaicin-induced inactivation of sensory neurons promotes a more aggressive gene expression phenotype in breast cancer cells. Breast Cancer Res Treat 2006; 99:351-364
55. Erin N, Boyer PJ, Bonneau RH, Clawson GA, Welch DR. Capsaicinmediated denervation of sensory neurons promotes mammary tumor metastasis to lung and heart. Anticancer Res 2004; 24:1003-1009
56. De Nicola AF, Brocca ME, Pietranera L, Garcia-Segura LM. Neuroprotection and sex steroid hormones:Evidence of estradiol-mediated protection in hypertensive encephalopathy. Mini Rev Med Chem 2012; 12: 1081-1089
57. Lewis KM, Harford-Wright E, Vink R, Ghabriel MN. Targeting classical but not neurogenic inflammation reduces peritumoral edema in secondary brain tumors. J Neuroimmunol 2012; 250:59-65
58. Gu YT, Zhang H, Xue YX. Dexamethasone enhances adenosine 50-Triphosphate-sensitive potassium channel expression in the blood-brain tumor barrier in a rat brain tumor model. Brain Res 2007; 1162:1-8
59. Ewing JR, Brown SL, Nagaraja TN, Bagher-Ebadian H, Paudyal R, Panda S, et al. MRI measurement of change in vascular parameters in the 9L rat cerebral tumor after dexamethasone administration. J Magn Reson Imaging 2008; 27:1430-1438
60. Watanabe Y, Asai H, Ishii T, Kiuchi S, Okamoto M, Taniguchi H, et al. Pharmacological characterization of T-2328, 2-fluoro-40-methoxy-30- [[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,10-biphenyl]-4- carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor. J Pharmacol Sci 2008; 106:121-127
61. Donkin JJ, Nimmo AJ, Cernak I, Blumbergs PC, Vink R. Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury. J Cereb Blood Flow Metab 2009; 29:1388-1398
62. Helps SC, Thornton E, Kleinig TJ, Manavis J, Vink R. Automatic nonsubjective estimation of antigen content visualized by immunohistochemistry using color deconvolution. Appl Immunohistochem Mol Morphol 2012; 20: 82-90
63. Harford-Wright E, Thornton E, Vink R. Angiotensin-converting enzyme (ACE) inhibitors exacerbate histological damage and motor deficits after experimental traumatic brain injury. Neurosci Lett 2010; 481:26-29
64. Johnson CL, Johnson CG. Characterization of receptors for substance P in human astrocytoma cells: Radioligand binding and inositol phosphate formation. J Neurochem 1992; 58:471-477
65. Eistetter HR, Mills A, Brewster R, Alouani S, Rambosson C, Kawashima E. Functional characterization of neurokinin-1 receptors on human U373MG astrocytoma cells. Glia 1992; 6:89-95
66. Munoz M, Gonzalez-Ortega A, Covenas R. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines. Invest New Drugs 2012; 30:529-540
67. Fowler CJ, Brannstrom G. Substance P enhances forskolin-stimulated cyclic AMP production in human UC11MG astrocytoma cells. Methods Find Exp Clin Pharmacol 1994; 16:21-28
68. Castro TA, Cohen MC, Rameshwar P. The expression of neurokinin-1 and preprotachykinin-1 in breast cancer cells depends on the relative degree of invasive and metastatic potential. Clin Exp Metastasis 2005; 22:621-628
69. Ramkissoon SH, Patel PS, Taborga M, Rameshwar P. Nuclear factor-kappaB is central to the expression of truncated neurokinin-1 receptor in breast cancer:Implication for breast cancer cell quiescence within bone marrow stroma. Cancer Res 2007; 67:1653-1659
70. Palma C, Nardelli F, Manzini S, Maggi CA. Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors. Br J Cancer 1999; 79:236-243
71. Fukuhara S, Mukai H, Kako K, Nakayama K, Munekata E. Further identification of neurokinin receptor types and mechanisms of calcium signaling evoked by neurokinins in the murine neuroblastoma C1300 cell line. J Neurochem 1996; 67:1282-1292
72. Palma C, Manzini S. Substance P induces secretion of immunomodulatory cytokines by human astrocytoma cells. J Neuroimmunol 1998; 81: 127-137
73. Munoz M, Perez A, Rosso M, Zamarriego C, Rosso R. Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines. Melanoma Res 2004; 14:183-188
74. Luo W, Sharif TR, Sharif M. Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-Activated protein kinase signaling pathway. Cancer Res 1996; 56:4983-4991
75. Munoz M, Rosso M, Aguilar FJ, Gonzalez-Moles MA, Redondo M, Esteban F. NK-1 receptor antagonists induce apoptosis and counteract substance Prelated mitogenesis in human laryngeal cancer cell line HEp-2. Invest New Drugs 2008; 26:111-118
76. Lang K, Drell TLt, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker KS, et al. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 2004; 112:231-238
77. Drell TLt, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 2003; 80:63-70
78. Ruff M, Schiffmann E, Terranova V, Pert CB. Neuropeptides are chemoattractants for human tumor cells and monocytes: A possible mechanism for metastasis. Clin Immunol Immunopathol 1985; 37:387-396
79. Nagakawa O, Ogasawara M, Fujii H, Murakami K, Murata J, Fuse H, et al. Effect of prostatic neuropeptides on invasion and migration of PC-3 prostate cancer cells. Cancer Lett 1998; 133:27-33
80. Ogasawara M, Murata J, Ayukawa K, Saimi I. Differential effect of intestinal neuropeptides on invasion and migration of colon carcinoma cells in vitro. Cancer Lett 1997; 116:111-116
81. Lewis KM, Harford-Wright E, Vink R, Nimmo AJ, Ghabriel MN. Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood-brain barrier during extravasation and brain invasion. Clin Exp Metastasis 2012; 30:1-12
82. Schilling T, Pecherstorfer M, Blind E, Kohl B, Wagner H, Ziegler R, et al. Glucocorticoids decrease the production of parathyroid hormone-related protein in vitro but not in vivo in the Walker carcinosarcoma 256 rat model. Bone 1996; 18:315-319
83. Gu YT, Xue YX, Wang P, Zhang H, Qin LJ. Dexamethasone enhances calcium-Activated potassium channel expression in blood-brain tumor barrier in a rat brain tumor model. Brain Res 2009; 1259:1-6
84. Gu YT, Qin LJ, Qin X, Xu F. The molecular mechanism of dexamethasonemediated effect on the blood-brain tumor barrier permeability in a rat brain tumor model. Neurosci Lett 2009; 452:114-118
85. Heiss JD, Papavassiliou E, Merrill MJ, Nieman L, Knightly JJ, Walbridge S, et al. Mechanism of dexamethasone suppression of brain tumor-Associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest 1996; 98:1400-1408
86. Nakagawa H, Groothuis DR, Owens ES, Fenstermacher JD, Patlak CS, Blasberg RG. Dexamethasone effects on [125I]albumin distribution in experimental RG-2 gliomas and adjacent brain. J Cereb Blood Flow Metab 1987; 7:687-701
87. Van Den Brenk HA, Kelly H, Orton C. Reduction by anti-inflammatory corticosteroids of clonogenic growth of allogeneic tumour cells in normal and irradiated tissues of the rat. Br J Cancer 1974; 29:365-372
88. Zhang M, Olsson Y. Hematogenous metastases of the human brain - characteristics of peritumoral brain changes: A review. J Neurooncol 1997; 35:81-89
89. Van Den Brenk HA, Stone M, Kelly H, Orton C, Sharpington C. Promotion of growth of tumour cells in acutely inflamed tissues. Br J Cancer 1974; 30:246-260
90. Lorger M, Felding-Habermann B. Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. Am J Pathol 2010; 176:2958-2971
91. Zhang M, Olsson Y. Reactions of astrocytes and microglial cells around hematogenous metastases of the human brain. Expression of endothelin-like immunoreactivity in reactive astrocytes and activation of microglial cells. J Neurol Sci 1995; 134:26-32
92. Donkin JJ, Cernak I, Blumbergs PC, Vink R. A substance P antagonist reduces axonal injury and improves neurologic outcome when administered up to 12 hours after traumatic brain injury. J Neurotrauma 2011; 28: 217-224
93. Bergstrom M, Hargreaves RJ, Burns HD, Goldberg MR, Sciberras D, Reines SA, et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry 2004; 55:1007-1012
94. Fitzgerald DP, Palmieri D, Hua E, Hargrave E, Herring JM, Qian Y, et al. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metastasis 2008; 25:799-810
95. He BP, Wang JJ, Zhang X, Wu Y, Wang M, Bay BH, et al. Differential reactions of microglia to brain metastasis of lung cancer. Mol Med 2006; 12:161-170